{"ok":true,"nota":{"id":"c437e6c01ca58403","slug":"una-vacuna-contra-el-citomegalovirus-protege-poco-frente-a-cepas-disti-c437e6","titulo":"Una vacuna contra el citomegalovirus protege poco frente a cepas distintas de la misma familia de virus","resumen":"Probaron en cobayos una vacuna bivalente contra el citomegalovirus y la compararon entre distintas cepas del virus. Encontraron que la protección se reduce cuando la cepa es diferente, por una respuesta débil de anticuerpos y por la evasión de la inmunidad celular.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Choi, K. Y., Qin, Y., El-Hamdi, N., McGregor, A.","url":"https://www.biorxiv.org/content/10.64898/2026.10.28.762556v1?rss=1","imagen":"/hoy/portada/c437e6c01ca58403","tema":"salud","subtemas":["citomegalovirus","vacunas","embarazo","sordera infantil","inmunidad"],"entidades":["GPCMV","TAMYC"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-29T00:00:00.000Z","indexTs":"2026-10-30T01:41:25.081Z","hash":"2b377c73e954d7faa6698abc76c061716e5ba54ddbda841cd03b4a8622269c5c","tsa":{"time":"Oct 30 01:42:19 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"El citomegalovirus es una de las principales causas de sordera y problemas cognitivos en recién nacidos, y todavía no hay vacuna. Este resultado muestra que no alcanza con proteger contra una sola variante del virus. Como el estudio es en animales, la vacuna humana sigue lejos, pero el mensaje para el diseño es claro.","quienFirma":"Universidad no especificada en el resumen","confianza":"preprint","consulta":null},"sello":{"hash":"2b377c73e954d7faa6698abc76c061716e5ba54ddbda841cd03b4a8622269c5c","sello":"869054acd566e52ddee73a7905aa238708eacc019ed26c22b76e4cd19857cbac","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6596450,"aleatorio":"8d1c91a00a6c1a4bdd361587b0f9f7991c51b5dfe6a6971810fd0733f135fb82","tiempo":"2026-10-30T01:42:00.000Z"},"nist":{"cadena":2,"pulso":2005159,"salida":"417517EA2867BB16B166609019A6A6E8E82E60D784744A268E2C76D6E48EAFB56CAC84C2DC56A6A8A6257CE2E1392EE256CB08E98B7713F796769875FE32226C","tiempo":"2026-10-30T01:41:00.000Z"},"noAntes":"2026-10-30T01:42:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 30 01:42:19 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Limited cross strain CMV protection by a bivalent (gB/pp65) vaccine is based on an impaired gB antibody response and evasion of pp65 cell mediated immunity","descripcion":"Congenital CMV (cCMV) is a leading cause of hearing loss and cognitive impairment in newborns and a vaccine is a high priority. The guinea pig with species-specific guinea pig cytomegalovirus (GPCMV) is the only small animal model for cCMV. Prior GPCMV vaccine studies have focused on prototype strain 22122 and not evaluated cross-strain protection, an important vaccine benchmark. The essential viral entry gB glycoprotein is an immunodominant antibody target and considered a corner stone of a CMV vaccine. Trimeric gB antigen induces potent neutralizing antibody titers but a clinical strain of GPCMV (TAMYC) is highly cell-associated limiting gB antibody cross-strain protection. In HCMV and GPC","pubDate":"2026-10-29","url":"https://www.biorxiv.org/content/10.64898/2026.10.28.762556v1?rss=1"},"indexado":"2026-10-30T01:41:25.081Z"}}